Methods for treating atopic dermatitis by administering an il-4r antagonist
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAshish BANSAL, Neil GRAHAM, Paola MINA-OSORIO, John DAVIS, Mohamed KAMAL
Life of this patent
Estimating the term…
Abstract
Methods for treating moderate-to-severe or severe atopic dermatitis in a pediatric subject are provided. In one aspect, the methods comprise administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.
Claims48
A method for treating atopic dermatitis (AD) or improving an AD-associated parameter in a subject, the method comprising:
- (a) selecting a subject with moderate-to-severe or severe AD, wherein the subject is ≥6 years to <12 years of age;
- and
- (b) administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, wherein the IL-4R antagonist is an anti-IL-4R antibody, or an antigen-binding fragment thereof, that comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2.
A method for treating atopic dermatitis (AD) or improving an AD-associated parameter in a subject, the method comprising:
- (a) administering a first dosing regimen of an IL-4R antagonist to a subject having moderate-to-severe AD or severe AD, wherein the subject is ≥6 years to <18 years of age;
- (b) determining whether the subject has an inadequate clinical response to the first dosing regimen;
- and
- (c) for a subject having an inadequate clinical response, administering a second dosing regimen of the IL-4R antagonist to the subject, wherein the second dosing regimen comprises administering the IL-4R antagonist at (i) a dose of 200 mg Q2W if the subject has a body weight <60 kg;
- or (ii) a dose of 300 mg Q2W if the subject has a body weight ≥60 kg;
- wherein the IL-4R antagonist is an anti-IL-4R antibody, or an antigen-binding fragment thereof, that comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2.
A method for treating AD or improving an AD-associated parameter in a subject, wherein the subject is ≥6 years to <18 years of age and has moderate-to-severe or severe AD, the method comprising subcutaneously administering to the subject an anti-IL-4R antibody, or an antigen-binding fragment thereof, that comprises the HCDRs of a HCVR comprising the amino acid sequence of SEQ ID NO:
- 1 and the LCDRs of a LCVR comprising the amino acid sequence of SEQ ID NO:2;
- wherein:
- (i) for a subject having a body weight of ≥15 kg to <30 kg, the anti-IL-4R antibody or antigen-binding fragment thereof is administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg Q4W;
- or
- (ii) for a subject having a body weight of ≥30 kg to <60 kg, the anti-IL-4R antibody or antigen-binding fragment thereof is administered at an initial dose of 400 mg followed by one or more secondary doses of 200 mg Q2W;
- or
- (iii) for a subject having a body weight of ≥60 kg, the anti-IL-4R antibody or antigen-binding fragment thereof is administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg Q2W.
42-47. (canceled)
A therapeutic dosage form of a pharmaceutical composition comprising an IL-4R antagonist, wherein administration of the dosage form for 16 weeks to a subject provides a mean serum concentration of the IL-4R antagonist of 80-100 mg/L.
Dependencies are inferred from the claim text.